Journal of the Neurological Sciences
Volume 203 , Pages 125-130 , 15 November 2002

Treatment options: The latest evidence with galantamine (Reminyl®)

References 

  1. Erkinjuntti T. Cerebrovascular dementia. Pathophysiology, diagnosis and treatment. CNS Drugs. 1999;12:35–48
  2. Rockwood K, Wentzel C, Hachinski V, Hogan DB, MacKnight C, McDowell I. Prevalence and outcomes of vascular cognitive impairment. Neurology. 2000;54:447–451
  3. Fratiglioni L, De Ronchi D, Aguero-Torres H. Worldwide prevalence and incidence of dementia. Drugs Aging. 1999;15:365–375
  4. Kalaria RN, Ballard C. Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis. Assoc. Disord. 1999;13(Suppl. 3):S115–S123
  5. Rockwood K, Bowler J, Erkinjuntti T, Hachinski V, Wallin A. Subtypes of vascular dementia. Alzheimer Dis. Assoc. Disord. 1999;13:S59–S63
  6. Maelicke A, Albuquerque X. Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease. Eur. J. Pharmacol. 2000;393:165–170
  7. Wallin A, Blennow K, Gottfries CG. Neurochemical abnormalities in vascular dementia. Dementia. 1989;1:120–130
  8. Gottfries CG, Blennow K, Karlsson I, Wallin A. The neurochemistry of vascular dementia. Dementia. 1994;5:163–167
  9. Tohgi H, Abe T, Kimura M, Saheki M, Takahashi S. Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer-type dementia. J. Neural Transm. 1996;103:1211–1220
  10. Ferrari R, Frasoldati A, Leo G, Torri C, Zini I, Agnati LF, et al.  Changes in nicotinic acetylcholine receptor subunit mRNAs and nicotinic binding in spontaneously hypertensive stroke prone rats. Neurosci. Lett. 1999;277:169–172
  11. Kumar V, Anand R, Messina J, Hartman R, Veach J. An efficacy and safety analysis of Exelon® in Alzheimer's disease patients with concurrent vascular risk factors. Eur. J. Neurol. 2000;7:159–169
  12. Mendez MF, Younesi FI, Perryman KM. Use of donepezil for vascular dementia: preliminary clinical experience. J. Neuropsychiatry Clin. Neurosci. 1999;11:268–270
  13. Wilcock GK, Lilienfeld S, Gaens E  on behalf of the Galantamine International-1 Study Group . Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: a multicentre randomised controlled trial. BMJ. 2000;321:1445–1448
  14. Raskind MA, Peskind ER, Wessel T, Yuan W  the Galantamine USA-1 Study Group . Galantamine in AD—a 6-month, randomized, placebo-controlled trial with a 6-month extension. Neurology. 2000;54:2261–2268
  15. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in Alzheimer's disease. Neurology. 2000;54:2269–2276
  16. Gauthier S, Ferris S. Outcome measures for probable vascular dementia and Alzheimer's disease with cerebrovascular disease. Int. J. Clin. Pract., Suppl. 2001;120:S29–S39
  17. Erkinjuntti T, Lilienfeld S. Galantamine shows efficacy in patients with Alzheimer's disease combined with cerebrovascular disease or probable vascular dementia. Poster presented at the In: 53rd Annual Meeting of the American Academy of Neurology, Philadelphia, PA, USA, May. 2001;
  18. Róman GC, Tatemichi TC, Erkinjuntti I, Cummings JL, Masdeu JC, Garcia JH, et al.  Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993;43:250–260
  19. Orgogozo JM, Abadie E. Vascular dementia: European perspectives. Alzheimer Dis. Assoc. Disord. 1999;13:S192–S200
  20. Gold G, Giannakopoulos P, Montex-Paixao JC, Herrmann FR, Mulligan R, Michel JP, et al.  Sensitivity and specificity of newly proposed clinical criteria for possible vascular dementia. Neurology. 1997;49:690–694
  21. Lopez OL, Larumbe MR, Becker JT, Rezek D, Rosen J, Klunk W, et al.  Reliability of NINDS-AIREN clinical criteria for the diagnosis of vascular dementia. Neurology. 1994;44:1240–1245
  22. O'Brien MD. Vascular dementia is underdiagnosed. Arch. Neurol. 1988;45:243–245
  23. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS/ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 1984;34:939–944
  24. Róman G. Diagnosis of vascular dementia and Alzheimer's disease. Int. J. Clin. Pract., Suppl. 2001;120:9–13
  25. Fishner B. Effect of propentofylline on disease progression in Alzheimer's disease and vascular dementia. Results of studies using the combined randomisation start/withdrawal design. Neurobiol. Aging. 1998;19:S302–S303
  26. Kittner B  European/Canadian Propentofylline Study Group . Clinical trials of propentofylline in vascular dementia. Alzheimer Dis. Assoc. Disord. 1999;13(Suppl. 3):S166–S171
  27. Orgogozo JM, Forette F. Efficacy of memantine in mild-to-moderate vascular dementia. Presented at the In: 6th International Springfield Symposium on Advances in Alzheimer Therapy, Stockholm, Sweden, 5–8 April. 2000;
  28. Wilcock G, Stoeffer A, Sahin K, Moebius HJ. Neuro-radiological findings and the magnitude of cognitive benefit by memantine treatment. A subgroup analysis of two placebo-controlled clinical trials in vascular dementia. Eur. Neuropsychopharmacol. 2000;10(Suppl. 3):S360
  29. Desmond DW, Erkinjuntti T, Sano M, Cummings JL, Bowler JV, Pasquier F, et al.  The cognitive syndrome of vascular dementia: implications for clinical trials. Alzheimer Dis. Assoc. Disord. 1999;13:S21–S29
  30. Rosen W, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am. J. Psychiatry. 1984;141:1356–1364
  31. Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B, et al.  Validity and reliability of the Alzheimer's Disease Cooperative Study—Clinical Global Impression of Change. Alzheimer Dis. Assoc. Disord. 1997;1(Suppl. 2):S22–S32
  32. Gelinas I, Gauthier L, McIntyre M, Gauthier S. Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. Am. J. Occup. Ther. 1999;53:471–481
  33. Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology. 1997;48(Suppl. 6):S10–S16
  34. Gauthier S, Rockwood K, Gélinas I, Sykes L, Teunisse S, Orgogozo JM, et al.  Outcome measures for the study of activities of daily living in vascular dementia. Alzheimer Dis. Assoc. Disord. 1999;13(Suppl. 3):S143–S147
  35. Lehfeld H, Reisberg B, Finkel S, Kanowski S, Wied V, Pittas J, et al.  Informant-rated activities-of-daily-living (ADL) assessments: results of a study of 141 items in the USA, Germany, Russia and Greece for the International ADL Scale Development Project. Alzheimer Dis. Assoc. Disord. 1997;11:S39–S44
  36. Tariot P. Current status and new developments with galantamine in the treatment of Alzheimer's disease. Expert Opin. Pharmacother. 2001;2:2027–2049
  37. Skoog I. Status of risk factors for vascular dementia. Neuroepidemiology. 1998;17:2–9
  38. Skoog I. The relationship between blood pressure and dementia: a review. Biomed. Pharmacother. 1997;51:367–375
  39. Meyer JS, Judd BW, Tawaklna T, Rogers RL, Mortel KF. Improved cognition after control of risk factors for multi-infarct dementia. JAMA. 1986;256:2203–2209
  40. Meyer JS, Rogers RL, McClintie K, Mortel KF, Lotfi J. Randomized clinical trial of daily aspirin therapy in multi-infarct dementia. A pilot study. J. Am. Geriatr. Soc. 1989;37:549–555
  41. Doody RS, Stevens JC, Beck C, Dubinsky RM, Kaye JA, Gwyther L, et al.  Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1154–1166
  42. Rother M, Erkinjuntti T, Roesnner M, Kittner B, Marcusson J, Karlsson I. Propentofylline in the treatment of Alzheimer's disease and vascular dementia. Dement. Geriatr. Cogn. Disord. 1998;9(Suppl. 1):36–43
  43. Pischel T. Long-term efficacy and safety of propentofylline in patients with vascular dementia. Results of a 12 months placebo-controlled trial. Neurobiol. Aging. 1998;19(Suppl. 4):S182

PII: S0022-510X(02)00267-8

Journal of the Neurological Sciences
Volume 203 , Pages 125-130 , 15 November 2002

Article Tools

* Image Usage & Resolution